272 related articles for article (PubMed ID: 14690879)
21. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness.
Krupitsky E; Nunes EV; Ling W; Gastfriend DR; Memisoglu A; Silverman BL
Addiction; 2013 Sep; 108(9):1628-37. PubMed ID: 23701526
[TBL] [Abstract][Full Text] [Related]
22. Precipitated withdrawal during maintenance opioid blockade with extended release naltrexone.
Fishman M
Addiction; 2008 Aug; 103(8):1399-401. PubMed ID: 18855831
[TBL] [Abstract][Full Text] [Related]
23. Does naltrexone affect craving in abstinent opioid-dependent patients?
Dijkstra BA; De Jong CA; Bluschke SM; Krabbe PF; van der Staak CP
Addict Biol; 2007 Jun; 12(2):176-82. PubMed ID: 17508990
[TBL] [Abstract][Full Text] [Related]
24. Treatment retention in adolescent patients treated with methadone or buprenorphine for opioid dependence: a file review.
Bell J; Mutch C
Drug Alcohol Rev; 2006 Mar; 25(2):167-71. PubMed ID: 16627307
[TBL] [Abstract][Full Text] [Related]
25. Effects of psychiatric comorbidity on treatment outcome in patients undergoing diamorphine or methadone maintenance treatment.
Schäfer I; Eiroa-Orosa FJ; Verthein U; Dilg C; Haasen C; Reimer J
Psychopathology; 2010; 43(2):88-95. PubMed ID: 20068379
[TBL] [Abstract][Full Text] [Related]
26. Risk factors for craving and relapse in heroin users treated with oral or implant naltrexone.
Hulse GK; Ngo HT; Tait RJ
Biol Psychiatry; 2010 Aug; 68(3):296-302. PubMed ID: 20537615
[TBL] [Abstract][Full Text] [Related]
27. Use of very low-dose naltrexone during opiate detoxification.
Mannelli P; Gottheil E; Buonanno A; De Risio S
J Addict Dis; 2003; 22(2):63-70. PubMed ID: 12703669
[TBL] [Abstract][Full Text] [Related]
28. Comparative treatment and mortality correlates and adverse event profile of implant naltrexone and sublingual buprenorphine.
Reece AS
J Subst Abuse Treat; 2009 Oct; 37(3):256-65. PubMed ID: 19394789
[TBL] [Abstract][Full Text] [Related]
29. Substance use and quality of life over 12 months among buprenorphine maintenance-treated and methadone maintenance-treated heroin-addicted patients.
Maremmani I; Pani PP; Pacini M; Perugi G
J Subst Abuse Treat; 2007 Jul; 33(1):91-8. PubMed ID: 17588494
[TBL] [Abstract][Full Text] [Related]
30. Injectable extended-release naltrexone for opioid dependence.
Woody GE; Metzger DS
Lancet; 2011 Aug; 378(9792):664-5; author reply 666. PubMed ID: 21856476
[No Abstract] [Full Text] [Related]
31. Favorable mortality profile of naltrexone implants for opiate addiction.
Reece AS
J Addict Dis; 2010 Jan; 29(1):30-50. PubMed ID: 20390697
[TBL] [Abstract][Full Text] [Related]
32. Vivitrex (Alkermes/Cephalon).
Heading CE
Curr Opin Investig Drugs; 2006 Jan; 7(1):81-8. PubMed ID: 16425675
[TBL] [Abstract][Full Text] [Related]
33. Naltrexone: a clinical perspective.
Greenstein RA; Arndt IC; McLellan AT; O'Brien CP; Evans B
J Clin Psychiatry; 1984 Sep; 45(9 Pt 2):25-8. PubMed ID: 6469933
[TBL] [Abstract][Full Text] [Related]
34. Concerns about injectable naltrexone for opioid dependence.
Wolfe D; Carrieri MP; Dasgupta N; Wodak A; Newman R; Bruce RD
Lancet; 2011 Apr; 377(9776):1468-70. PubMed ID: 21529930
[No Abstract] [Full Text] [Related]
35. Response to Degenhardt et al.: 'depot naltrexone use for opioid dependence in Australia: large-scale use of an unregistered medication in the absence of data on safety and efficacy'.
Brewer C
Drug Alcohol Rev; 2008 Jul; 27(4):447-8; author reply 448-9. PubMed ID: 18584398
[No Abstract] [Full Text] [Related]
36. Comparative study of the effectiveness of slow-release morphine and methadone for opioid maintenance therapy.
Eder H; Jagsch R; Kraigher D; Primorac A; Ebner N; Fischer G
Addiction; 2005 Aug; 100(8):1101-9. PubMed ID: 16042640
[TBL] [Abstract][Full Text] [Related]
37. Mortality in heroin users 3 years after naltrexone implant or methadone maintenance treatment.
Tait RJ; Ngo HT; Hulse GK
J Subst Abuse Treat; 2008 Sep; 35(2):116-24. PubMed ID: 17931824
[TBL] [Abstract][Full Text] [Related]
38. Naltrexone implants compared to methadone: outcomes six months after prison release.
Lobmaier PP; Kunøe N; Gossop M; Katevoll T; Waal H
Eur Addict Res; 2010; 16(3):139-45. PubMed ID: 20424458
[TBL] [Abstract][Full Text] [Related]
39. Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD).
Digiusto E; Shakeshaft A; Ritter A; O'Brien S; Mattick RP;
Addiction; 2004 Apr; 99(4):450-60. PubMed ID: 15049745
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review.
Johansson BA; Berglund M; Lindgren A
Addiction; 2006 Apr; 101(4):491-503. PubMed ID: 16548929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
